| |
| |
|
| Insider
Information: |
Sender Gary |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
26,722 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$158,374 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
26,722 |
|
|
| Total
Value |
$158,374 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -40.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Nabriva Therapeutics AG |
NBRV |
Chief Financial Officer |
2021-02-28 |
20,472 |
|
0 |
Premium* |
|
|
Schrodinger, Inc. |
SDGR |
Director |
2023-06-15 |
6,250 |
2021-03-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SDGR |
Schrodinger, Inc. |
Director |
– • – |
2023-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
6,250 |
6,250 |
0 |
- |
|
| SDGR |
Schrodinger, Inc. |
Director |
– • – |
2021-03-08 |
4 |
S |
$66.55 |
$1,914,838 |
D/D |
(28,775) |
0 |
0 |
% |
|
| SDGR |
Schrodinger, Inc. |
Director |
– • – |
2021-03-08 |
4 |
OE |
$5.31 |
$303,479 |
D/D |
28,775 |
28,775 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2021-02-28 |
4 |
D |
$2.39 |
$74 |
D/D |
(31) |
20,472 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2021-01-31 |
4 |
D |
$2.62 |
$97 |
D/D |
(37) |
20,503 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-12-31 |
4 |
D |
$2.42 |
$77 |
D/D |
(32) |
20,540 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-11-30 |
4 |
D |
$0.43 |
$133 |
D/D |
(312) |
205,728 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-10-31 |
4 |
D |
$0.50 |
$155 |
D/D |
(312) |
206,040 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-09-30 |
4 |
D |
$0.53 |
$166 |
D/D |
(312) |
206,352 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-08-31 |
4 |
D |
$0.62 |
$193 |
D/D |
(312) |
206,664 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-08-20 |
4 |
D |
$0.65 |
$2,075 |
D/D |
(3,204) |
206,976 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
210,180 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-07-31 |
4 |
D |
$0.76 |
$237 |
D/D |
(312) |
198,930 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-06-30 |
4 |
D |
$0.67 |
$210 |
D/D |
(312) |
199,242 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-05-31 |
4 |
D |
$1.14 |
$356 |
D/D |
(312) |
199,554 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-04-30 |
4 |
D |
$0.55 |
$165 |
D/D |
(301) |
193,679 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-03-31 |
4 |
D |
$0.58 |
$173 |
D/D |
(301) |
193,980 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-02-28 |
4 |
D |
$1.35 |
$406 |
D/D |
(301) |
194,281 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
183,669 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2020-01-31 |
4 |
D |
$1.35 |
$5,798 |
D/D |
(4,295) |
78,669 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2019-08-21 |
4 |
D |
$2.08 |
$7,051 |
D/D |
(3,390) |
19,214 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2019-08-21 |
4/A |
S |
$2.08 |
$7,051 |
D/D |
(3,390) |
19,214 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2019-08-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
22,604 |
0 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2018-05-23 |
4 |
B |
$4.57 |
$9,140 |
D/D |
2,000 |
6,200 |
2.74 |
- |
|
| NBRV |
Nabriva Therapeutics AG |
Chief Financial Officer |
• – – |
2017-09-22 |
4 |
B |
$8.21 |
$16,420 |
D/D |
2,000 |
4,200 |
2.74 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
